Iterum Therapeutics Q1 net loss $4.9M; preparing for ORLYNVAH launch by Q4 2025

Iterum Therapeutics plc

Net loss of $4.9M in Q1 2025 vs $7.1M in Q1 2024; non-GAAP net loss $3.3M vs $5.8M.
Cash and equivalents $12.7M at March 31, 2025; extended runway into 2026 via $5M registered direct offering and ~$1M ATM proceeds.
Preparing for potential launch of ORLYNVAH (oral sulopenem) for uUTIs by Q4 2025; FDA approved October 2024.
Repaid $6.5M 6.500% exchangeable senior subordinated notes due 2025 in January 2025.
R&D expense fell to $0.6M (from $4.0M) due to REASSURE trial wind-down; G&A rose to $2.8M on pre-commercialization costs.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-069794
form_type: 8-K
ticker: ITRMF
cik: 0001659323
company_name: Iterum Therapeutics plc
filed_at: 2025-05-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.236742+00:00
generated_at: 2026-05-21T16:19:31.151769+00:00
sec_items: ["2.02", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-069794
json_url: https://secwatch.observer/filing/0000950170-25-069794.json
markdown_url: https://secwatch.observer/filing/0000950170-25-069794.md
text_url: https://secwatch.observer/filing/0000950170-25-069794.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017025069794/0000950170-25-069794-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017025069794/itrm-20250513.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-069794

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.